Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Gall

Showing results (341-350 of 362) with videos related to

Pageof 37
Sort By:
Medrxiv : the Preprint Server for Health Sciences|September 29, 2025
Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibodySharana Mahomed, Nonhlanhla N Mkhize, Leonid A Serebryannyy, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|May 15, 2009
Rapid gynogenetic mapping of Xenopus tropicalis mutations to chromosomesMustafa K Khokha, Vladimir Krylov, Michael J Reilly, et al.
Scientific Reports|May 19, 2022
Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potencyCindy X Cai, Nicole A Doria-Rose, Nicole A Schneck, et al.
Vaccines|November 24, 2022
Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1Li Ou, Krishana Gulla, Andrea Biju, et al.
Science Translational Medicine|October 4, 2023
An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challengeAlec W Freyn, Caroline Atyeo, Patricia L Earl, et al.
FEBS Open Bio|December 28, 2013
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organsFiona M Keane, Tsun-Wen Yao, Stefanie Seelk, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Science (New York, N.Y.)|August 3, 2019
A proof of concept for structure-based vaccine design targeting RSV in humansMichelle C Crank, Tracy J Ruckwardt, Man Chen, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Pageof 37

Showing results (341-350 of 362) with videos related to

Sort By:
Pageof 37
Medrxiv : the Preprint Server for Health Sciences|September 29, 2025
Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibodySharana Mahomed, Nonhlanhla N Mkhize, Leonid A Serebryannyy, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|May 15, 2009
Rapid gynogenetic mapping of Xenopus tropicalis mutations to chromosomesMustafa K Khokha, Vladimir Krylov, Michael J Reilly, et al.
Scientific Reports|May 19, 2022
Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potencyCindy X Cai, Nicole A Doria-Rose, Nicole A Schneck, et al.
Vaccines|November 24, 2022
Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1Li Ou, Krishana Gulla, Andrea Biju, et al.
Science Translational Medicine|October 4, 2023
An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challengeAlec W Freyn, Caroline Atyeo, Patricia L Earl, et al.
FEBS Open Bio|December 28, 2013
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organsFiona M Keane, Tsun-Wen Yao, Stefanie Seelk, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Science (New York, N.Y.)|August 3, 2019
A proof of concept for structure-based vaccine design targeting RSV in humansMichelle C Crank, Tracy J Ruckwardt, Man Chen, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Pageof 37